Thierry  Muanza

Assistant Professor

Oncology

Address:
Radiation Oncology
Segal Cancer Centre
Jewish General Hospital
Room G-002
3755 Côte-Ste-Catherine Road
Montreal, QC H3T 1E2

Telephone: 514-340-8288
E-mail: thierry.muanza@mcgill.ca

Education: M.D., Université de Sherbrooke, QC; M.Sc., Northeastern University; B.A., Suffolk University, Boston, MA; Translational Research Fellowship, NIH, Bethesda, MD 

Clinical Focus: Breast Cancer; Central Nervous System Tumours; Lung Cancer; Adolescent & Young Adult Oncology


Recent Presentations:

Muanza T, Ibrahim M, Fournier B, Dalzell M-A, Shallwani S, Sintharaphone A, Sateren W. Randomized Clinical Trial of a Progressive Exercise Program for Young Women With Breast Cancer Undergoing Radiation Therapy. ASTRO 57th Annual Scientific Meeting, October 18-21, 2015 in San Antonio, Tx, USA.

Zhang H, Zhang P, Gilbert M, Aldape K, Chakravarti A, Magliocco A, Klimowicz A, D'Souza W, Corn B, Hunter G, Muanza T, Dicker A, Vigneault E, Brachman D, Bovi J, Robins HI, Sahijdak W, Won M, Mehta M. NRG Oncology/RTOG 0525 Role of Machine Learning Analytic Tools for Survival Prediction of GBM Patients Using Clinical Parameters. ASTRO 57th Annual Scientific Meeting, October 18-21, 2015 in San Antonio, Tx, USA.

Muanza T, Kumala S, Heravi M, Bekerat H, Sadr MS, Del maestro R, Jean-Claude B. Novel binary molecule ZRBA1, as a unique MGMT independent radiosensitizer to treat malignant Gliomas. CARO 2015 Annual Scientific Meeting, September 9-12, 2015, Kelowna BC, Canada. September 2015.

Roger Stupp et al on behalf of the EF-14 Trial investigators. Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM. 19th Annual Scientific Meeting of the Society for Neuro-Oncology, November 15, 2014, Miami, USA.

M.B. Azam, Y.S. Rho, A. Mamo1, S. Sahebjam2, T. Muanza, M.-C. Guiot, J. Al-Shami1, R. Sharma, P. Kavan. Patterns and efficacy of bevacizumab use across treatment lines in glioblastoma. ESMO 2014 Congress, 26-30 September, Madrid, Spain.

Muanza T, M. Heravi, B. Fournier, S. Kumala. Potentiation of radiation response by a novel EGFR/DNA targeting molecule in a triple negative breast cancer model. International Conference on Translational Research in Radio-Oncology and Physics for Health in Europe, Geneva, ICTR February 10-14, 2014


Recent Publications:

Shakir SI, Pelmus M, AncaFlorea, Boileau J-F, Guiot M-C, Di Maio S, Muanza T. Synchronous Metastatic Skull Base Chordoma to the Breast: case report and literature review. Current Oncology #2896 (in press).

Mitra Heravi, Slawomir Kumala, Zakaria Rachid, Nada Tomic, Slobodan Devic, Bertrand J. Jean-Claude, Danuta Radzioch and Thierry M. Muanza. ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model. International Journal of Radiation Oncology*Biology*Physics. Volume 92(2): 399-406. June 2015

Jad Alshami, Marie-Christine Guiot, Scott Owen, Petr Kavan, Neil gibson, Flavio Solca, Agnieszka Cseh, David Reardon, Thierry Muanza. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget 6(32). DOI: 10.18632/ oncotarget.5297. 2015.

Tamim Niazi, Gary Mok, Mitra Heravi, Te Vuong, Raquel Aloyz, Lawrence Panasci, Thierry Muanza. Effects of DNA-PK inhibition on DNA repair and cell survival in irradiated gastric cancer cell line N87. Current Oncology 2014 Apr;21(2):91-6

Mitra Heravi, Slawomir Kumala, Zakaria Rachid, Nada Tomic, Slobodan Devic, Bertrand J. Jean-Claude, Danuta Radzioch and Thierry M. Muanza. ZRBA1 a mixed EGFR/ DNA targeting molecule potentiates radiation response through delayed DNA damage repair process in a triple negative breast cancer model. Int J Radiat Oncol Biol Phys (in press, ROB-D-14_01043R2).

Jad Alshami, Marie-Christine Guiot, Scott Owen, Petr Kavan, Neil gibson, Flavio Solca, Agnieszka Cseh, David Reardon, Thierry Muanza. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. (in press, ACD-15-00069).